Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Develops neuro-metabolic therapeutics for schizophrenia and ALS
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
Pitching Newpath Partners? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room